Related Experiment Video
Updated: Aug 7, 2025
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Soluble Guanylate Cyclase β1 Subunit Represses Human Glioblastoma Growth
Haijie Xiao1, Haifeng Zhu2,3, Oliver Bögler4,5
1Department of Biochemistry and Molecular Medicine, The George Washington University, 2300 I Street NW, Washington, DC 20037, USA.
Abstract:
Malignant glioma is the most common and deadly brain tumor. A marked reduction in the levels of sGC (soluble guanylyl cyclase) transcript in the human glioma specimens has been revealed in our previous studies. In the present study, restoring the expression of sGCβ1 alone repressed the aggressive course of glioma. The antitumor effect of sGCβ1 was not associated with enzymatic activity of sGC since overexpression of sGCβ1 alone did not influence the level of cyclic GMP. Additionally, sGCβ1-induced inhibition of the growth of glioma cells was not influenced by treatment with sGC stimulators or inhibitors. The present study is the first to reveal that sGCβ1 migrated into the nucleus and interacted with the promoter of the TP53 gene. Transcriptional responses induced by sGCβ1 caused the G0 cell cycle arrest of glioblastoma cells and inhibition of tumor aggressiveness. sGCβ1 overexpression impacted signaling in glioblastoma multiforme, including the promotion of nuclear accumulation of p53, a marked reduction in CDK6, and a significant decrease in integrin α6. These anticancer targets of sGCβ1 may represent clinically important regulatory pathways that contribute to the development of a therapeutic strategy for cancer treatment.
Insights
Restoring soluble guanylyl cyclase beta 1 (sGCβ1) expression inhibits aggressive glioma growth by targeting the TP53 gene promoter. This novel mechanism leads to cell cycle arrest and reduced tumor aggressiveness in glioblastoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Malignant glioma is a deadly brain tumor with reduced soluble guanylyl cyclase (sGC) transcript levels observed previously.
- The specific role of sGC subunits in glioma progression remains largely undefined.
Purpose of the Study:
- To investigate the direct role of sGCβ1 in repressing glioma aggressiveness.
- To elucidate the molecular mechanisms underlying the anti-glioma effects of sGCβ1.
Main Methods:
- Overexpression of sGCβ1 in human glioma cells.
- Assessment of cyclic GMP levels and response to sGC modulators.
- Nuclear translocation and chromatin immunoprecipitation assays to identify gene targets.
- Analysis of cell cycle progression, p53 accumulation, CDK6, and integrin α6 expression.
Main Results:
- sGCβ1 overexpression alone repressed glioma aggressiveness without affecting cyclic GMP levels or sGC activity.
- sGCβ1 was found to translocate into the nucleus and interact with the TP53 gene promoter.
- sGCβ1 induced G0 cell cycle arrest in glioblastoma cells, reduced CDK6, and decreased integrin α6 expression, promoting p53 nuclear accumulation.
Conclusions:
- sGCβ1 exhibits potent antitumor activity in glioma independent of its enzymatic function.
- Nuclear sGCβ1 acts as a transcriptional regulator, targeting TP53 to inhibit glioblastoma growth and aggressiveness.
- sGCβ1 and its downstream targets represent potential therapeutic strategies for malignant glioma.
Related Concept Videos
01:09GPCRs Regulate Adenylyl Cylase Activity
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:22Activation and Inactivation of G Proteins